- CA$10.33m
- CA$30.71m
- CA$1.54m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -163.04% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.79 | 2.65 | 1.95 | 5.31 | 1.54 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmaCielo Ltd. is a Canada-based global company with a focus on ethical and sustainable cultivation, processing and supplying of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company’s all-natural cannabis into standardized, medicinal-grade dried cannabis flower, cannabis oil extracts and cannabis-related products sold in bulk to pharmaceutical companies and medicinal cannabis distributors globally. In Colombia, PharmaCielo Colombia is a fully licensed cultivator, producer, and distributor of both TetraHydroCannabinol and Cannabidiol medical cannabis. Ubiquo is a knowledge management and medical consultation system. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate.
Directors
- Henning Von Koss PRE
- Scott Laitinen CFO
- Andres Botero COO
- David Gordon OTH
- Marc Lustig LED
- Douglas Bache IND
- Claudia Jimenez IND
- Matteo Pellegrini IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2024
- Incorporated
- May 30th, 2017
- Public Since
- January 30th, 2018
- No. of Employees
- 268
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 187,828,800
- Address
- 82 Richmond Street East, TORONTO, M5C 1P1
- Web
- https://www.pharmacielo.com/
- Phone
- +1 4163158741
- Auditors
- BDO Canada LLP
Upcoming Events for PCLO
Q3 2025 Pharmacielo Ltd Earnings Release
Similar to PCLO
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
What is the Pharmacielo share price?
As of Today at 04:38 UTC, shares in Pharmacielo are trading at CA$0.06. This share price information is delayed by 15 minutes.
How has the Pharmacielo share price performed this year?
Shares in Pharmacielo last closed at CA$0.06 and the price had moved by -57.69% over the past 365 days. In terms of relative price strength the Pharmacielo share price has underperformed the Toronto Stock Exchange 300 Composite Index by -64.73% over the past year.
What are the analyst and broker recommendations for Pharmacielo?
The overall consensus recommendation for Pharmacielo is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharmacielo dividend yield?
Pharmacielo does not currently pay a dividend.
Does Pharmacielo pay a dividend?
Pharmacielo does not currently pay a dividend.
When does Pharmacielo next pay dividends?
Pharmacielo does not currently pay a dividend.
How do I buy Pharmacielo shares?
To buy shares in Pharmacielo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmacielo?
As of the previous close price of CA$0.06, shares in Pharmacielo had a market capitalisation of CA$10.33m.
Where are Pharmacielo shares listed?
Here are the trading details for Pharmacielo:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: PCLO
What kind of share is Pharmacielo?
Based on an overall assessment of its quality, value and momentum Pharmacielo is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmacielo share price forecast for 2025?
The analyst consensus target price for shares in Pharmacielo is CA$2.50. That is 4445.45% above the last closing price of CA$0.06.
Analysts covering Pharmacielo currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Pharmacielo share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmacielo. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -46.39%.
As of the last closing price of CA$0.06, shares in Pharmacielo were trading -32.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmacielo PE Ratio?
The Pharmacielo PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmacielo?
Pharmacielo's management team is headed by:
- Henning Von Koss - PRE
- Scott Laitinen - CFO
- Andres Botero - COO
- David Gordon - OTH
- Marc Lustig - LED
- Douglas Bache - IND
- Claudia Jimenez - IND
- Matteo Pellegrini - IND